SCHEMBL3604278

SCHEMBL3604278

COc1ccc(N(S)C(N)=O)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALOX5 P09917 2/20 0.41
HTT P42858 1/20 0.41
PARP1 P09874 2/20 0.41
PARP10 Q53GL7 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
PARP4 Q9UKK3 1/20 0.41
KDM4E B2RXH2 2/20 0.39
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 2/20 0.39
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14662766 0.87 POLB (0.42) POLBSMN1; SMN2ALOX5HTTPARP1
SCHEMBL2590633 0.84 CA12 (0.48) SMN1; SMN2ALOX5HTTCA1CA2
SCHEMBL4199227 0.80 TDP1 (0.38) SMN1; SMN2ALOX5HTTPARP1KDM4E
SCHEMBL3607811 0.79 EPHX2 (0.43) SMN1; SMN2ALOX5PARP1PARP10CA1
SCHEMBL11539989 0.77 ALDH1A1 (0.43) SMN1; SMN2ALOX5KDM4EMEN1TSHR
SCHEMBL526027 0.74 CA1 (0.52) SMN1; SMN2ALOX5PARP1PARP10CA1
SCHEMBL14925281 0.73 KMT2A (0.46) SMN1; SMN2HTTKEAP1NFE2L2MEN1
SCHEMBL8809964 0.73 KMT2A (0.43) SMN1; SMN2HTTKDM4EKEAP1NFE2L2
SCHEMBL73373 0.72 PARP1 (0.53) PARP1
SCHEMBL653135 0.72 S100B (0.50) POLBSMN1; SMN2HTTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed
EP-1687285-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS Novartis AG (CH) 2006-08-09 EP disclosed
WO-2005047273-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors FLT3, FLT1, FLT4 POLB 2006/4885SMN1; SMN2 4364/4885ALOX5 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.